Metsera, Inc.’s Quiet Period Set To End Tomorrow (NASDAQ:MTSR)

Metsera’s (NASDAQ:MTSR) quiet period is set to expire on Wednesday, March 12th. Metsera had issued 15,277,778 shares in its IPO on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. During Metsera’s quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analysts Set New Price Targets

MTSR has been the topic of a number of recent research reports. Cantor Fitzgerald began coverage on Metsera in a research note on Tuesday, February 25th. They issued an “overweight” rating on the stock. Bank of America initiated coverage on Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $38.00 price objective for the company. Guggenheim initiated coverage on Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price target for the company. Finally, Evercore ISI started coverage on Metsera in a report on Tuesday, February 25th. They issued an “outperform” rating for the company.

Metsera Stock Performance

MTSR stock opened at $25.03 on Tuesday. Metsera has a 1-year low of $24.19 and a 1-year high of $32.81.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.